Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SLGL 
Sol Gel Technologies Ltd (SLGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: SLGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $50
1 Year Target Price $50
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.35% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 99.10M USD | Price to earnings Ratio - | 1Y Target Price 50 |
Price to earnings Ratio - | 1Y Target Price 50 | ||
Volume (30-day avg) 1 | Beta 1.38 | 52 Weeks Range 4.02 - 52.26 | Updated Date 11/13/2025 |
52 Weeks Range 4.02 - 52.26 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.25% | Operating Margin (TTM) 65.06% |
Management Effectiveness
Return on Assets (TTM) -7.33% | Return on Equity (TTM) -10.21% |
Valuation
Trailing PE - | Forward PE 9.34 | Enterprise Value 88913550 | Price to Sales(TTM) 5.73 |
Enterprise Value 88913550 | Price to Sales(TTM) 5.73 | ||
Enterprise Value to Revenue 4.69 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 2785787 | Shares Floating 549970 |
Shares Outstanding 2785787 | Shares Floating 549970 | ||
Percent Insiders 70 | Percent Institutions 15.52 |
About Sol Gel Technologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-23 | CEO & Executive Chairman Mr. Moshe Arkin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.sol-gel.com |
Full time employees 34 | Website https://www.sol-gel.com | ||
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.